<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Aug. 19, 2019 (HealthDay News) — After any underlying causes are addressed and diet and lifestyle strategies are implemented, prescription omega-3 fatty acids (n-3 FAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) or EPA only, at a dose of 4 g\/day are effective for lowering triglycerides as monotherapy or in combination with other agents, according to an American Heart Association science advisory published online Aug. 19 in Circulation<\/i>.<\/p>\n
Ann C. Skulas-Ray, Ph.D., from the University of Arizona in Tucson, and colleagues summarized the lipid and lipoprotein effects resulting from pharmacological doses of n-3 FAs (>3 g EPA+DHA) on the basis of new scientific data.<\/p>\n
The researchers found that treatment of very high triglycerides with 4 g\/day EPA+DHA reduced triglycerides by \u226530 percent, with simultaneous increases in low-density lipoprotein cholesterol; low-density lipoprotein cholesterol was not raised with EPA only. n-3 FAs with EPA+DHA or EPA only seemed about comparable for triglyceride lowering when used to treat hypertriglyceridemia; when used as monotherapy or in combination with a statin, n-3 FAs with EPA+DHA or EPA did not increase low-density lipoprotein cholesterol. Non-high-density lipoprotein cholesterol and apolipoprotein B were modestly decreased in the largest trials of 4 g\/day prescription n-3 FA. In a randomized trial of EPA only in high-risk patients treated with a statin, use of n-3 FA (4 g\/day) resulted in a 25 percent reduction in major adverse cardiovascular events.<\/p>\n
“We concluded that treatment with 4 grams daily of any of the available prescription choices is effective and can be used safely in conjunction with statin medicines that lower cholesterol,” Skulas-Ray said in a statement.<\/p>\n
Several authors disclosed financial ties to the pharmaceutical and nutrition industries.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n